ProMIS Neurosciences Inc PMN

Nothing like a bit of fear to promote PMN310 science

[retiredcop]

https://www.science.org/content/article/clinical-trial-participants-autopsy-brain-exam-stoke-alzheimers-drug-fears

[M101]

wow, and they didn't see it coming so they haven't censored it yet

[M101]

Interesting how they first describe AD as "the woman’s hard-to-diagnose, preexisting condition" before later clarifying that "Like all Alzheimer’s patients, the woman was also at risk of a condition called cerebral amyloid angiopathy (CAA)" then mitigating it with "It takes sophisticated, expensive brain imaging to detect signs of CAA" So I guess this

[Gbathat]

table setter becoming a red carpet... hopefully they don't slow down the IND approval due to this and have a good understading of the science behind PMN310. https://www.science.org/content/article/scientists-tie-third-clinical-trial-death-experimental-alzheimer-s-drug "Although lecanemab targets a soluble version of beta amyloid, it also binds to the extracellular beta amyloid

[M101]

5 MRIs each year to make sure each lecanemab patient is not one of the unlucky few who actually has the pre-existing condition know as AD.   Eisai should rebrand again, call it (whatever condition it is that Lecanemab actually cures) Esiai Disease or ED, it's just more marketable.  

[retiredcop]

This type of news will not really have any impact on the IND...what it does is create controversy with the previous treatments and people talk about it and what happens when PMN310 does not have the same side effects... we jump to the front of the line with scientists and of course the public who are struggling to have any kind of AD treatment  . Bad news is good news for us!!! 

[M101]

You're probably right that it won't have any effect on the IND evaluation, but that still begs the question how did aducanumab and lecanemab ever pass P1 in the first place? How was brain bleeding not a disqualifying safety condition back during their IND phases?   Because it was expensive? Because the technology for diagnosis is relatively novel? Because it doesn't show up well

[Gbathat]

I concur on all the above.  These other drugs are rolling out the red carpet for PMN310.  After reviewing the IND info on FDA's website, it does look like a pretty straight forward process.  And it seems like they have a program in place already for pre-review of the IND info, which is probably where any delays would have already taken place. If we have relatively low or better

[M101]

Irrational exhuberance, the propellant for a moon shot is still efficacy. But at least we could get off the ground if managment would do a better job of promoting what next-generation means. It's not like communications tech where you can just google it, you can't just say the phrase here and then leave it to big pharma's spin machine, they're the enemy.